CHRS — Coherus Oncology, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CHRS
| date | signal | measured base rate |
|---|---|---|
| 2026-05-11 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-05 | Wahlstrom Mats Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-05 | O'Donnell-Tormey Jill Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-05 | Newton Charles W. Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-05 | Newcomer Lee Nisley Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-05 | Karachun Rita A Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-05 | Satvat Ali J. Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-06-05 | Ryan Michael Lee Director | Grant or award | 30.0K | 0.00 | 0 |
| 2026-01-23 | Lanfear Dennis M President & CEO | Grant or award | 375.0K | 0.00 | 0 |
| 2026-01-22 | McMichael Bryan J Chief Financial Officer | Grant or award | 112.5K | 0.00 | 0 |
| 2026-01-20 | Lanfear Dennis M President & CEO | Shares withheld for tax | 11.8K | 1.55 | 18.4K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 17.5M | 10.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.2M | 5.5M |
| SAMSARA BIOCAPITAL, LLC | 5.8M | 3.4M |
| GEODE CAPITAL MANAGEMENT, LLC | 5.3M | 3.1M |
| Kohlberg Kravis Roberts & Co. L.P. | 5.1M | 3.0M |
| STATE STREET CORP | 3.9M | 2.3M |
| TWO SIGMA INVESTMENTS, LP | 3.9M | 2.3M |
| Alyeska Investment Group, L.P. | 3.8M | 2.2M |
| CM Management, LLC | 3.5M | 2.1M |
| TANG CAPITAL MANAGEMENT LLC | 3.2M | 1.9M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Coherus Oncology, Inc. (CHRS) filed form 8-K · 2026-08-17 · SEC EDGAR
- Coherus Oncology, Inc. (CHRS) filed form 8-K · 2026-08-17 · SEC EDGAR
- Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript · 2026-08-13
Ask the AI about CHRS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →